Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research concludes that finasteride significantly reduces dihydrotestosterone levels and prostate size in men with BPH and may improve urinary symptoms, with greater baseline prostate size predicting more pronounced benefits compared to placebo.

Tamsulosin works faster, but both drugs have similar effects after 6 months.

In this study, a 12-week treatment with Angelicae Gigantis Radix and Glycyrrhizae Radix complex was well tolerated and showed therapeutic effects on moderate lower urinary tract symptoms in men.

This paper discusses risk factors and prevention strategies for acute urinary retention secondary to benign prostatic hyperplasia, emphasizing the role of PSA levels and the benefits of medications like finasteride and alpha-blockers, but reports no new clinical results.

This review discusses the efficacy of the lipidosterolic extract of Serenoa repens for treating lower urinary tract symptoms and reports no new clinical results; the authors propose further examination of the existing literature and guidelines.

This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.

This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.

This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.

Early balding may be a sign of future prostate problems.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

This study reports on biofeedback treatment for dysfunctional voiding in three adult cases, providing insights into this condition when diagnosed beyond childhood.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

Hair loss can be an early sign of prostate enlargement.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.

This study found that finasteride improved urodynamic measures of obstruction in men with benign prostatic enlargement and lower urinary tract symptoms, with continued improvement over two years of treatment.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

This study aimed to identify characteristics of patients who fail to void during pressure-flow studies, which limits the determination of the cause behind their lower urinary tract symptoms.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This study found that combining tamsulosin and finasteride significantly improved urinary symptoms and IPSS scores in elderly patients with benign prostatic hyperplasia compared to finasteride alone, with good safety profiles.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

This study reports that saw palmetto may effectively treat benign prostatic hyperplasia symptoms and potentially stimulate hair growth with generally mild side effects.